The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 16, 2021
Filed:
Oct. 05, 2016
Applicant:
Cedars-sinai Medical Center, Los Angeles, CA (US);
Inventors:
Sungyong You, Los Angeles, CA (US);
Michael Freeman, West Hollywood, CA (US);
Jayoung Kim, Beverly Hills, CA (US);
Beatrice Knudsen, Los Angeles, CA (US);
Assignee:
Cedars-Sinai Medical Center, Los Angeles, CA (US);
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12Q 1/6886 (2018.01); G16B 25/00 (2019.01); G16B 20/00 (2019.01); A61K 33/243 (2019.01); G16B 20/20 (2019.01); G16B 25/10 (2019.01); A61K 31/337 (2006.01); A61K 31/4166 (2006.01); A61K 31/506 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); A61K 31/337 (2013.01); A61K 31/4166 (2013.01); A61K 31/506 (2013.01); A61K 33/243 (2019.01); G16B 20/00 (2019.02); G16B 20/20 (2019.02); G16B 25/00 (2019.02); G16B 25/10 (2019.02); C12Q 2600/112 (2013.01); C12Q 2600/158 (2013.01);
Abstract
The invention provides various methods for classifying prostate cancers into subtypes. The classification methods may be used to diagnose or prognose prostate cancers. In one embodiment, the subtypes are PCS1, PCS2, or PCS3. In one embodiment, the PCS1 subtype is most likely to progress to metastatic disease or prostate cancer specific mortality when compared to the PCS2 subtype or PCS3 subtype. In one embodiment, the PCS1 subtype is resistant to enzalutamide.